Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways

作者：Chunxiao Li, Jianguo Gao, Xingyong Wan, Yi Chen, Chengfu Xu, Zemin Feng, Hang Zeng, Yiming Lin, Han Ma, Ping Xu, Chaohui Yu, Youming Li · 发表于：World Journal of Gastroenterology · 年份：2019 · DOI：10.3748/wjg.v25.i34.5120 · 被引用次数：89 · 研究领域：Liver Disease Diagnosis and Treatment、Genomics, phytochemicals, and oxidative stress、Drug-Induced Hepatotoxicity and Protection

BACKGROUND: Allyl isothiocyanate (AITC), a classic anti-inflammatory and antitumorigenic agent, was recently identified as a potential treatment for obesity and insulin resistance. However, little is known about its direct impact on the liver. AIM: To investigate the effect and underlying mechanism of AITC in nonalcoholic fatty liver disease (commonly referred to as NAFLD). METHODS: To establish a mouse and cellular model of NAFLD, C57BL/6 mice were fed a high fat diet (HFD) for 8 wk, and AML-12 cells were treated with 200 μM palmitate acid for 24 h. For AITC treatment, mice were administered AITC (100 mg/kg/d) orally and AML-12 cells were treated with AITC (20 μmol/L). RESULTS: through the Sirt1/AMPK and NF-κB signaling pathways. Importantly, further studies showed that the curative effect of AITC on lipid accumulation was abolished by siRNA-mediated knockdown of either Sirt1 or AMPKα in AML-12 cells. CONCLUSION: AITC significantly ameliorates hepatic steatosis and inflammation by activating the Sirt1/AMPK pathway and inhibiting the NF-κB pathway. Therefore, AITC is a potential therapeutic agent for NAFLD.